Introduction

Figure 1.Structure of glutamate. Glutamate binding promotes stronger signal transduction to aid in G-protein activation by mGlu2.

mGlu2 plays vital roles in memory formation, pain management, and addiction, which makes it an important drug target for Parkinson’s Disease,Schizophrenia, cocaine dependence, and many other neurological conditions.

Structure

Overall Structure

Cryo-EM studies of mGlu2 have yielded adequate structural maps of mGlu2 in various activation states. These maps provided clearer understanding of the conformational changes between the inactive and active states of mGlu2^[1]. Due to conformational changes, mGlu2 moves between different states: inactive, intermediate, PAM bound, and active (Figure 3). The overall of the mGlu2 is composed of 3 main parts: a ligand binding , followed by a linker to the that contains 7 α-helices (7TM) on both the α and β chains. The VFT and CRD are located in the intracellular domain (ICD), while the TMD is located in the extracellular domain (ECD) (Figure 2). The TMD aids in the binding of the G-protein.

Figure 2.Show the regions of mGlu2.

mGlu2 is a homodimer. Dimerization of mGlu2 is required to relay glutamate binding from the ECD to its TMD. The homodimer of mGlu2 contains an . Occupation of both ECDs with the agonist, glutamate, is necessary for a fully active mGlu2^[3]. However, only one chain in the dimer is responsible for activation of the G-protein, this suggests an asymmetrical signal transduction mechanism for mGlu2^[1].

Inactive State

A few hallmarks of the of mGlu2 are the in the open conformation, well separated , and distinct orientation of the 7TM. The most critical component of the inactive form is the formed by the 7 α-helices in the α and β chains of the 7TM. The inactive structure of mGlu2 is mediated mainly by helices 3 and 4 on both the α and β chains of the dimer through hydrophobic interactions. These between both transmembrane helices stabilize inactive conformation of mGlu2^[1].

Figure 3. Demonstrates the conformational changes of mGlu2.

Intermediate Form

No Cryo-EM structures are currently available for the intermediate form, but it is an important state for the full activation of mGlu2. While in the intermediate form, Glutamate, the agonist of mGlu2, binds both agonist binding sites. The is formed by both lobes of the VFT. The structure of mGlu2 will still remain in the inactive form upon two glutamates binding. The binding of glutamate, however, promotes signaling down the receptor ^[1].

PAM and NAM Bound Form

A positive allosteric modulator (PAM) or a negative allosteric modulator (NAM) can bind to mGlu2. PAM and NAM induce different conformational changes, which result in different outcomes. to the receptor, induces conformational changes, which helps to promote greater affinity for G protein binding. PAM binds in a binding pocket that is created by helices III, V, VI, VII in the . Within helix VI, the hydrophobic binding is composed of W773, F776, L777, and F780. Due to spatial hindrance caused by the binding of PAM, helix VI is shifted downward, causing conformational changes that increase G-protein binding affinity. NAM, however, reduces the affinity for G protein binding. NAM binds to the same binding pocket as PAM and also interacts with residue W773, but NAM occupies the binding site a little deeper than PAM. This causes NAM to push the side chain of W773 towards helix VII^[1].

Figure 4.PAM located binding pocket. PAM, JNJ-40411813, is shown in magenta and colored by atom type, four labelled binding helices (III, V, VI, and VII) create the binding pocket in the 7TM region for PAM binding. PAM binding promotes G-protein activation by mGLu2.

Active State

Upon binding of the PAM, helix VI is shifted downward in the TMD. This downward shift induces a reorientation of the TMD from its original TM3-TM4 asymmetric dimer interface in the inactive form to an . The downward shift of helix VI is crucial for the receptor’s transformation from the inactive to the active form for 2 main reasons: (1) reorientation breaks key interactions in the TMD that stabilize the inactive form and (2) repositioning of in the TMD to assist in the binding and recognitions of the . The G-protein is made up of three subunits: , , and a .

G-Protein Recognition

Transition to the active state also reorients helix lll in both monomers to enable binding to the G-protein: Yet only one chain is required for full receptor activation. The intracellular region of helix lll contributes the main interactions with the alpha subunit of the G-protein. Intracellular Loop 2 also builds a polar interaction network with the G-protein through its ionic interactions with the of the G-protein. Lastly, mGlu2 residue E666 forms a salt bridge with residue (R32) on the α-subunit which further destabilizes the inactive conformation^[1].

G-protein Binding

The PAM induced downward shift of helix IV coupled with the reorientation of the transmembrane domain to a TM6-TM6 asymmetric interface, opens up a cleft on the intracellular surface of the receptor. This cleft allows a , from the last 4 terminals of the α-subunit of the G-protein, to move in adjacent to helix IV in the transmembrane domain. Within this interaction, on the hook participates in hydrophobic interactions with Intracellular loop 2 and helix 4. These interactions allow the C-terminal region of the G-protein α-subunit to bind in the shallow groove formed by intracellular loops 2 and 3 and residues on helices 3 and lV^[1].The receptor is now with the dimer coupled only to one G-protein. The ]VFT is in the closed conformation resulting in a tighter form. The TMD helices are also reoriented in both monomers to form an asymmetric dimer interface.

Clinical Relevance

mGluRsoccur both presynaptically and postsynaptically in the Central Nervous System ^[4]. mGluRs play a variety of roles, such as in disease, synaptic plasticity, and modulation of other receptors^[4]. Manipulation of these receptors are starting to be used as drug targets for Parkinson's Disease, Fragile X Syndrome, and Schizophrenia.

Schizophrenia

Schizophreniais a chronic brain disorder that affects a person’s ability to think, feel, and behave clearly. The exact cause of Schizophrenia is unknown currently ^[5]. The symptoms from the disease can vary from patient to patient, but they can be broken down into positive, negative, and cognitive symptoms^[6]. Although antipsychotic drugs help to treat Schizophrenia, these drugs only target positive symptoms and have limited efficacy against negative and cognitive symptoms ^[7]. mGlu2 receptors are a therapeutic target for Schizophrenia, as mGlu2 receptors are expressed in regions associated with Schizophrenia, such as the prefrontal cortex, hippocampus, the thalamus, and amygdala ^[6]. Specifically mGlu2 agonists, LY379268 and LY40439, exhibits antipsychotic properties by increasing dopamine extracellular levels^[7]. Increasing dopamine levels improves negative symptoms of Schizophrenia ^[7]. mGlu2 agonists also increase cortical serotonin levels, which is a property seen in many antipsychotic drugs. These clinical properties give potential for mGlu2 and its agonists as future treatments for Schizophrenia^[7].